Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.00 Consensus Price Target from Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAXGet Free Report) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $43.00.

BCAX has been the topic of several research reports. Morgan Stanley began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price objective on the stock. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. TD Cowen assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating for the company. Stifel Nicolaus began coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price objective on the stock. Finally, Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price for the company.

Check Out Our Latest Stock Report on Bicara Therapeutics

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BCAX. SG Americas Securities LLC acquired a new position in shares of Bicara Therapeutics in the fourth quarter valued at $147,000. Cinctive Capital Management LP bought a new stake in shares of Bicara Therapeutics during the third quarter worth approximately $229,000. Barclays PLC acquired a new position in shares of Bicara Therapeutics in the third quarter valued at approximately $255,000. Jane Street Group LLC bought a new position in shares of Bicara Therapeutics during the third quarter worth approximately $309,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $358,000.

Bicara Therapeutics Stock Performance

Shares of NASDAQ:BCAX opened at $11.92 on Monday. The company has a 50 day moving average price of $17.46. Bicara Therapeutics has a fifty-two week low of $11.51 and a fifty-two week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAXGet Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Bicara Therapeutics Company Profile

(Get Free Report

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

See Also

Analyst Recommendations for Bicara Therapeutics (NASDAQ:BCAX)

Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.